11/26/2007

The FDA has accepted Schering-Plough Corp.'s new drug application for asenapine, an oral treatment for schizophrenia and symptoms of bipolar disorder. Schering-Plough owns rights to asenapine through Organon BioSciences NV, which it acquired last week.

Full Story:
MarketWatch

Related Summaries